ZHONGSHAN, China - s4story -- On March 28, 2025, Transtek Medical(stock code: [300562.SZ]) announced its 2024 annual results, reporting solid growth across key financial metrics. For the reporting period, Transtek achieved revenue of RMB 984 million, representing an 11.28% year-on-year increase. Net profit attributable to shareholders rose sharply by 78.55% to RMB 61.36 million. The company's overall gross margin improved to 35.07%, up 4.13 percentage points from the previous year.

Throughout 2024, Transtek continued to advance its strategic positioning as a provider of medical-grade remote health monitoring devices and services. The company expanded its chronic disease management product portfolio, including smart blood pressure monitors, medical-grade ECG vests, blood glucose meters, body composition scales, OTC hearing aids, and smart wearables. These devices cover key health parameters such as blood pressure, blood glucose, body composition, PPG, ECG, physical activity, sleep, atrial fibrillation, and arrhythmias, and have obtained medical certifications across China, the U.S., Europe, and South Korea.

More on S For Story

• Solomon Eye Appoints Dr. Nancy Draskovic as Clinical Director of Ocular Surface Disease
• 150% Increase in Fiscal Q2 Sales vs Previous Year to $750,000; Continuous Record Quarters & Profitability for Homebuilding Product: Innovative Designs
• Use Dogecoin (DOGE) to mine Bitcoin (BTC) and earn passive income at home
• New Novel Tells a Whale of a Traveler's Tale (Minus the Whale)
• New Edition Release: James Langston's "What to Do When You Don't Know What to Do" Offers Real Hope for Life's Hardest Moments

In product development, Transtek made strategic progress in smart blood glucose monitoring, with products registered with the U.S. FDA and listed by SIGIS. Its subsidiary focusing on remote ECG services secured approval for the iSENSE 12-lead smart ECG vest as a Class II medical device.

Leveraging technological innovation, Transtek launched an AI-driven cardiovascular health model, integrating smart monitoring devices with AI healthcare services to deliver inclusive digital chronic disease management.

Looking forward, Transtek will continue to enrich its medical-grade product lineup, strengthen its technological leadership, and deepen its presence in global markets. The company remains committed to driving high-quality growth and expanding its role in the digital health ecosystem.

Founded in 2000, Transtek is committed to multiple health fields such as remote health and chronic disease management, providing customers with medical-grade "RPM devices" and "cloud services". Transtek also provides one-stop connectivity technology, device management, and fulfillment services for Remote Patient Monitoring (RPM) providers. Transtek has established a co-branded solution named TeleRPM since 2019, it stands for Quality & Value which is the best of Transtek. TeleRPM is an integrated solution which includes cellular blood pressure monitor, cellular weight scale, cellular blood glucose meter and all-round BLE package with AnyHub solution. Also, TeleRPM is open and scalable, and Transtek will leverage their expertise to help customers realize greater value, potential and outcomes.

More on S For Story

• European Tech Startup RoarFun discovers a gap in the U.S. market with a branded racing simulator rental at Atlanta's MRO Americas Aviation Convention
• Degrees of Justice: Attorney Frank Walker Charts the Future of Criminal Justice with Ph.D Degree
• The Jesse Roldan Team and Biz Hub Financial Successfully Facilitate One-Day Closing for Investor Deal in Hellertown, PA
• Gold Recording Artist Melekel Melachim Drops Dual Release: Reggae Album Meets Digital Flipbook
• How Does Google Crawl Websites?